VC Fund Dossiers

PJC is a quietly solid fund that's been grinding for over two decades without much fanfare. They've delivered 1 unicorn (Nexamp), 2 IPOs (Expensify, Yandex), and 45 acquisitions - respectable returns but nothing that screams top-tier. The Gina Raimondo connection is interesting but also potentially problematic given the ethics questions around her prominent billing on their website while serving as Governor. David Martirano seems like a solid operator with real investment banking and M&A experience, but the team composition feels a bit thin for a fund that's been around this long. They're clearly competent at picking decent companies and helping them get to exit, but they're not going to give you the brand cachet or network effects of top Boston funds.

Redmile is one of the most respected healthcare crossover funds in the game, but they're essentially a hedge fund with venture capital aspirations. Jeremy Green built his reputation as a sharp healthcare analyst at Citi before launching Redmile, and his European perspective on biotech gives him edge that most US-centric funds lack. The good news: they have real money ($6.5B AUM), genuine expertise, and will stick with you through public markets - rare in today's VC world. The reality check: this isn't your typical founder-friendly VC. They're investors, not advisors, and they evaluate opportunities with hedge fund rigor. If your biotech has solid science and a clear path to meaningful revenue, they're fantastic. If you need hand-holding or warm introductions to potential customers, look elsewhere.